Nirasha Ramchurren
YOU?
Author Swipe
View article: Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma
Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma Open
View article: Merkel cell polyomavirus-specific and CD39+CLA+ CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinoma
Merkel cell polyomavirus-specific and CD39+CLA+ CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinoma Open
View article: T antigen–specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma
T antigen–specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma Open
Merkel cell carcinoma (MCC) is a highly immunogenic skin cancer primarily induced by Merkel cell polyomavirus, which is driven by the expression of the oncogenic T antigens (T-Ags). Blockade of the programmed cell death protein-1 (PD-1) pa…
View article: Data used in "Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma"
Data used in "Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma" Open
Data generated from the clinical trials, CITN-10 (NCT02243579) and CITN-13 (NCT03063632), analyzing the in vivo responses to anti-PD-1 monotherapy or anti-PD-1 interferon-gamma combination therapy in patients with advanced mycosis fungoide…
View article: Data used in "Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma"
Data used in "Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma" Open
Data generated from the clinical trials, CITN-10 (NCT02243579) and CITN-13 (NCT03063632), analyzing the in vivo responses to anti-PD-1 monotherapy or anti-PD-1 interferon-gamma combination therapy in patients with advanced mycosis fungoide…
View article: A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials
A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials Open
Introduction Immunotherapy is an effective treatment for a subset of cancer patients, and expanding the benefits of immunotherapy to all cancer patients will require predictive biomarkers of response and immune-related adverse events (irAE…
View article: 94 CyTOF and serum proteomics show distinct differences in immune responses between mycosis fungoides and sezary syndrome to mono- and combination anti-PD-1 immunotherapy
94 CyTOF and serum proteomics show distinct differences in immune responses between mycosis fungoides and sezary syndrome to mono- and combination anti-PD-1 immunotherapy Open
Background Cutaneous T cell Lymphoma (CTCL) is a rare malignancy of CD4+ T cells that has few treatment options. Mycosis Fungoides (MF) and Sezary Syndrome (SS) are the most common subtypes of CTCL, with MF confined to the skin and SS a le…
View article: 1045 High dimensional profiling of merkel cell polyomavirus-specific T cells in response to anti-PD-1 immunotherapy
1045 High dimensional profiling of merkel cell polyomavirus-specific T cells in response to anti-PD-1 immunotherapy Open
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer often associated with clonal integration of Merkel cell polyomavirus (MCPyV) and expression of T antigen oncoproteins in 80% of cases with the remainder of cases caused by…
View article: Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome Open
The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and…
View article: Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome Open
The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and…
View article: Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses Open
To uncover underlying mechanisms associated with failure of indoleamine 2,3-dioxygenase 1 (IDO1) blockade in clinical trials, we conducted a pilot, window-of-opportunity clinical study in 17 patients with newly diagnosed advanced high-grad…
View article: Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma Open
Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically unmet need for predictive biomarkers of response. Herein, w…
View article: 299 Broad T antigen-specific CD8+ T cell repertoire is associated with response to PD-1 blockade in virus positive merkel cell carcinoma
299 Broad T antigen-specific CD8+ T cell repertoire is associated with response to PD-1 blockade in virus positive merkel cell carcinoma Open
Background Merkel cell carcinoma (MCC) is an aggressive human skin cancer primarily induced by Merkel Cell Polyomavirus (MCPyV) driven by expression of the oncogenic T antigens (T-Ags): Large T and Small T antigen. Checkpoint inhibition th…
View article: New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy
New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy Open
View article: IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC) Open
Background Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a…
View article: Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma Open
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The …
View article: Pembrolizumab in mycosis fungoides with PD-L1 structural variants
Pembrolizumab in mycosis fungoides with PD-L1 structural variants Open
Key Points PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation. PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors.
View article: Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma Open
Anti-PD-1 immunotherapies have transformed cancer treatment, yet the determinants of clinical response are largely unknown. We performed CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced cutaneous T c…
View article: Cytometry datasets analyzed in FAUST manuscript
Cytometry datasets analyzed in FAUST manuscript Open
Cytometry data analyzed in FAUST manuscript: https://doi.org/10.1016/j.patter.2021.100372
View article: Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma Open
Anti-PD-1 immunotherapies have transformed cancer treatment, yet the determinants of clinical response are largely unknown. We performed CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced cutaneous T c…
View article: PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy Open
Background Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated w…
View article: 263 Pleiotropic effects of IL-7 in prostate cancer patients receiving Sipuleucel-T vaccination
263 Pleiotropic effects of IL-7 in prostate cancer patients receiving Sipuleucel-T vaccination Open
Background Sipuleucel-T (Provenge) is the first therapeutic vaccination approved by the FDA so far, indicated for advanced metastatic prostate cancer patients. Despite an improvement of the overall survival, the benefits of the therapy are…
View article: Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study Open
PURPOSE To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS). PATIENTS AND METHODS CITN-10 is a single-arm, multicenter phase II trial of 24 patients with a…
View article: Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy Open
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for advanced MCC (aMCC) demonstrate increased progression-free sur…
View article: Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy Open
Cancer-specific T and B cell responses generally track with disease burden during PD-1 blockade, in proportion to presence of antigen. Intratumoral TCR clonality was significantly greater in VP-MCC than VN-MCC tumors, suggesting expansion …
View article: Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab Open
While the binomial presence or absence of PD-L1 expression in the TME was not sufficient to predict response to anti-PD-1 in patients with MCC, we show that quantitative assessments of PD-1+ and PD-L1+ cell densities as well as the geograp…